What type of study is this?

August 26, 2025Liver InternationalOpen Access

Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study

View Full Paper

Ask AI

Bookmark

Ivosidenib treatment resulted in a median progression-free survival of 6.9 months, significantly better than 2.1 months with FOLFOX/CAPOX.
The overall survival for patients on ivosidenib was 15.9 months, compared to 9.0 months for those on FOLFOX/CAPOX.
This multicenter retrospective study analyzed 46 advanced IDH1 mutant cholangiocarcinoma patients across 11 European institutions.
About 8.7% of patients experienced grade 3 or higher adverse events during treatment, indicating manageable safety.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational study shows improved progression-free survival and overall survival with ivosidenib in IDH1 mutant cholangiocarcinoma, indicating it as a viable second-line treatment option.

Cite This Study

Niger et al. (2025) studied this question.

synapsesocial.com/papers/68af6203ad7bf08b1eae2c9e https://doi.org/10.1111/liv.70295

View Full Paper

Ask AI

Bookmark

Implication

Observational study shows improved progression-free survival and overall survival with ivosidenib in IDH1 mutant cholangiocarcinoma, indicating it as a viable second-line treatment option.

Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study

Key Points

Discussion

Implication

Cite This Study

Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider